Early data from the anti-LAG3 relatlimab used as simultaneous dual blockade targeting PD-1 together with LAG3 produced an objective response rate of 11% in melanoma patients progressing after anti-PD-1/PD-L1 monotherapy [85]. The gene discussed is LAG3; the disease is melanoma.